Literature DB >> 4045245

Leprosy in the United States, 1971-1981.

M A Neill, A W Hightower, C V Broome.   

Abstract

In the period 1971-1981, 1,835 cases of leprosy were reported in the United States; only 10% of these cases were indigenous. Since 1977, the number of new cases reported each year has risen because of an increase in imported cases of disease, a situation reflecting the increased number of refugees and immigrants who have entered the United States from areas endemic for leprosy. Forty-five of the 50 states reported cases. In only 25% of the imported cases were the patients known to have had leprosy at the time of immigration; the remaining 75% were diagnosed in this country. The highest rate of disease onset for this latter group occurred within 12 months after entry into the United States, but cases continued to be reported 10 years after entry. Active refugee resettlement programs have widely distributed persons with leprosy, contacts of diseased persons, and persons from endemic areas throughout the 50 states, a situation necessitating the development of expertise by medical professionals and public health officials in the diagnosis, treatment, and long-term follow-up of patients with leprosy.

Entities:  

Mesh:

Year:  1985        PMID: 4045245     DOI: 10.1093/infdis/152.5.1064

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Imported leprosy in the United States, 1978 through 1988: an epidemic without secondary transmission.

Authors:  T D Mastro; S C Redd; R F Breiman
Journal:  Am J Public Health       Date:  1992-08       Impact factor: 9.308

Review 2.  Leprosy: a primer for Canadian physicians.

Authors:  Andrea K Boggild; Jay S Keystone; Kevin C Kain
Journal:  CMAJ       Date:  2004-01-06       Impact factor: 8.262

3.  The effect of phenolic glycolipid-1 from Mycobacterium leprae on the antimicrobial activity of human macrophages.

Authors:  M A Neill; S J Klebanoff
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.